EGFR and neoplasm: Upon administration, keynatinib binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling, and leads to cell death in EGFR T790M-expressing tumor cells.